Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers using acylhydrazide compounds.
本发明涉及使用酰
肼化合物抑制、调节和/或调节可溶性、球形、非纤维化、神经毒性淀粉样β1-42寡聚体从淀粉样β1-42单体形成的方法。本发明还涉及使用酰
肼化合物治疗患有与可溶性、球形、非纤维化、神经毒性淀粉样β1-42寡聚体形成有关的疾病的患者的方法。